RetinAI Expands Operations with a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies
BERN, Switzerland & BOSTON--(BUSINESS WIRE)-- #AI--RetinAI Medical AG (“RetinAI”), is a leader in clinical and imaging data management software and advanced analytics for ophthalmology, is excited to announce the launch of its first U.S.-based office, located in Boston, MA. This expansion will support further growth within the U.S. market, building upon existing collaborations with U.S.-based pharmaceutical companies and its partnership with Heidelberg Engineering to distribute RetinAI’s Disease AI A